GlassScriptPhysician profile
Grant S Johnson
NPI 1851778609
$11,807.08
in general payments reported to CMS, 2019-2025
47 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.44 · 2020: $760 · 2021: $1,793 · 2022: $2,176 · 2023: $4,162 · 2024: $1,526 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,878 · Travel and Lodging: $2,062 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,878.44 |
| Travel and Lodging | $2,061.53 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,714.58 | 2020-2024 | Axonics, Bulkamid |
| Procept Biorobotics Corporation | $1,027.72 | 2021-2025 | Aquabeam Robotic System, Aquabeam System |
| Boston Scientific Corporation | $938.87 | 2020-2025 | Lithovue, Lumenis Pulse 120h, Spaceoar Vue System - 10ml |
| Pfizer INC. | $714.01 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $646.18 | 2023-2025 | Gemtesa, Orgovyx |
| Urogen Pharma, INC. | $625.39 | 2021-2025 | Jelmyto |
| Janssen Biotech, INC. | $605.28 | 2021-2025 | Erleada, Akeega, Balversa |
| Astellas Pharma US INC | $518.91 | 2019-2023 | Myrbetriq |
| Myovant Sciences INC. | $372.37 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $245.04 | 2021-2022 | |
| Tolmar, INC. | $243.44 | 2023-2025 | Eligard, Jatenzo |
| Medtronic, INC. | $226.79 | 2021-2025 | Interstim |
| Laborie Medical Technologies Corp. | $212.29 | 2022-2025 | |
| Teleflex LLC | $192.26 | 2021-2022 | |
| Antares Pharma, INC. | $175.90 | 2021-2025 | Xyosted |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $175.25 | 2020-2022 | |
| Abbvie INC. | $170.59 | 2023-2025 | |
| Astellas Pharma Global Development | $141.54 | 2024 | Xtandi |
| Srs Medical Systems, INC. | $140.66 | 2021 | |
| Medtronic USA, INC. | $124.53 | 2020 | |
| Novo Nordisk INC | $123.90 | 2021-2025 | Ozempic, Rybelsus |
| Olympus America INC. | $122.18 | 2024-2025 | Itind System |
| Angiodynamics, INC. | $110.21 | 2022 | |
| Blue Earth Diagnostics | $109.53 | 2022-2023 | |
| Allergan, INC. | $109.21 | 2020-2022 | |
| Clarus Therapeutics INC. | $108.91 | 2021 | |
| Coloplast Corp | $99.55 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $93.94 | 2021-2022 | |
| Stryker Corporation | $89.32 | 2024-2025 | Aequalis Ascend Flex, 1788 |
| Urovant Sciences INC | $86.68 | 2022 | |
| Dendreon Pharmaceuticals LLC | $65.65 | 2020-2024 | Provenge |
| Merck Sharp & Dohme LLC | $57.16 | 2023 | Keytruda, Lynparza |
| Myriad Genetic Laboratories, INC. | $55.32 | 2024-2025 | Prolaris |
| Dornier Medtech America, INC | $50.43 | 2024 | Dornier Medtech |
| Hollister Incorporated | $39.21 | 2022 | |
| Millicent US INC | $36.04 | 2023-2024 | Intrarosa, Femring |
| 180 Medical, INC. | $32.76 | 2021-2022 | |
| Rochester Medical Corporation | $31.57 | 2022 | |
| Bioprotect Medical, INC. | $25.64 | 2025 | Bioprotect Balloon Implant System |
| Amgen INC. | $24.67 | 2022 | |
| Innovation Technologies INC | $23.88 | 2025 | Irrisept |
| Progenics Pharmaceuticals, INC. | $22.49 | 2023 | Pylarify |
| Viiv Healthcare Company | $21.52 | 2023 | Apretude |
| Photocure INC | $16.56 | 2024 | Cysview |
| Astrazeneca Pharmaceuticals LP | $15.18 | 2022 | |
| Rti Surgical, INC | $12.23 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.